Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 6
2006 4
2007 3
2008 3
2009 2
2011 2
2012 3
2013 2
2014 2
2015 2
2018 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance.
Kenny JR, Ramsden D, Buckley DB, Dallas S, Fung C, Mohutsky M, Einolf HJ, Chen L, Dekeyser JG, Fitzgerald M, Goosen TC, Siu YA, Walsky RL, Zhang G, Tweedie D, Hariparsad N. Kenny JR, et al. Among authors: Walsky RL. Drug Metab Dispos. 2018 Sep;46(9):1285-1303. doi: 10.1124/dmd.118.081927. Epub 2018 Jun 29. Drug Metab Dispos. 2018. PMID: 29959133
Pharmacokinetics of the natural antibiotic negamycin.
Guo J, Miele EW, Chen A, Luzietti RA, Zambrowski M, Walsky RL, Buurman ET. Guo J, et al. Among authors: Walsky RL. Xenobiotica. 2015;45(7):625-33. doi: 10.3109/00498254.2015.1006301. Epub 2015 Mar 3. Xenobiotica. 2015. PMID: 25733027
Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group.
Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, Lim HK, MacLauchlin C, Prakash C, Surapaneni S, Tse S, Upthagrove A, Walsky RL, Wen B, Zeng Z. Yu H, et al. Among authors: Walsky RL. Drug Metab Dispos. 2015 Apr;43(4):620-30. doi: 10.1124/dmd.114.059345. Epub 2015 Feb 5. Drug Metab Dispos. 2015. PMID: 25655830
Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E, Walsky RL, Luzietti RA Jr, Harris JJ, Kosa RE, Goosen TC, Zientek MA, Obach RS. Tseng E, et al. Among authors: Walsky RL. Drug Metab Dispos. 2014 Jul;42(7):1163-73. doi: 10.1124/dmd.114.057000. Epub 2014 Apr 15. Drug Metab Dispos. 2014. PMID: 24737844
Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.
Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, Galvin M, Gupta A, Hale M, Johnson N, Luo W, McGrath F, Pietras M, Price S, Sathe AG, Sasaki JC, Snow D, Walsky RL, Kern G. Keirstead ND, et al. Among authors: Walsky RL. Toxicol Sci. 2014 Feb;137(2):278-91. doi: 10.1093/toxsci/kft247. Epub 2013 Nov 4. Toxicol Sci. 2014. PMID: 24189134
In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.
Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. Obach RS, et al. Among authors: Walsky RL. Clin Pharmacol Ther. 2005 Dec;78(6):582-92. doi: 10.1016/j.clpt.2005.09.004. Clin Pharmacol Ther. 2005. PMID: 16338274 Review. No abstract available.
In vitro cytochrome P450 inhibition and induction.
Walsky RL, Boldt SE. Walsky RL, et al. Curr Drug Metab. 2008 Nov;9(9):928-39. doi: 10.2174/138920008786485128. Curr Drug Metab. 2008. PMID: 18991590 Review.
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha.
Kalgutkar AS, Chen D, Varma MV, Feng B, Terra SG, Scialis RJ, Rotter CJ, Frederick KS, West MA, Goosen TC, Gosset JR, Walsky RL, Francone OL. Kalgutkar AS, et al. Among authors: Walsky RL. Xenobiotica. 2013 Nov;43(11):963-72. doi: 10.3109/00498254.2013.791004. Epub 2013 Apr 30. Xenobiotica. 2013. PMID: 23631744
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, Goosen TC. Walsky RL, et al. Drug Metab Dispos. 2012 May;40(5):1051-65. doi: 10.1124/dmd.111.043117. Epub 2012 Feb 22. Drug Metab Dispos. 2012. PMID: 22357286
27 results
Jump to page
Feedback